Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05492123 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 14 sitesv5
  2. Study sites revised (14)v4
  3. Site details revised at 1 of 14 sitesv3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Aug 31, 2026 to Dec 31, 2026
    • Study completion date: Aug 31, 2026 to Mar 31, 2028
    • Start date changed from estimate of Aug 1, 2022 to Aug 30, 2022
    • Site details revised at 14 of 14 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.
Trial Details
NCT Number NCT05492123
Lead Sponsor Hospital Israelita Albert Einstein
Collaborators: Bristol-Myers Squibb, Brava
Conditions
(from sponsor)		 Uterine Cervical Neoplasms
Related terms Uterine Cervical Neoplasms
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov